L'IMMUNOTERAPIA ADOTTIVA NEL TRATTAMENTO POST-CHIRURGICO DEL CARCINOMA POLMONARE NON A PICCOLE CELLULE

Translated title of the contribution: Adoptive immunotherapy in the postoperative treatment of non-small cell lung cancer

G. B. Ratto, C. Melioli, G. Fantino, E. Tassara, M. Ponte, M. Angelini, E. Spessa, C. Semino, S. Rovida

Research output: Contribution to journalArticle

Abstract

This study has been carried out to evaluate the efficacy of Adoptive Immunotherapy (AI) with TIL (Tumor Infiltrating Lymphocytes) cells and recombinant Interleukin-2 (rIL-2) in patients who underwent surgery for non small cell lung cancer (NSCLC) at Stage II, IIIa or IIIb. Seventy-one patients were stratified according to the disease Stage, randomized and treated with AI or standard therapies (Chemo-radiotherapy in Stage III; no therapy in Stage II). TIL cells, obtained from the removed specimens, were in vitro expanded and infused i.v. Subcutaneous administration of rIL-2, starting at the TIL infusion day, lasted for 3 months. For Stage II patients, the survival curve in the AI Group was similar to that in the Control Group. For Stage IIIa patients, survival tended to be higher in the AI Group with respect to the Control Group. For Stage IIIb patients, survival was significantly (p <0.05) better in the AI Group. The Performance Status, as far as Stage III patients are concerned, was improved in the AI Group, with respect to the Control Group. The number of intrathoracic recurrences was lower (50%) in patients undergoing AI, while no difference between Groups was found for distant relapse.

Original languageItalian
Pages (from-to)82-87
Number of pages6
JournalChirurgia
Volume8
Issue number1-2
Publication statusPublished - 1995

Fingerprint

Adoptive Immunotherapy
Non-Small Cell Lung Carcinoma
Tumor-Infiltrating Lymphocytes
Control Groups
Therapeutics
Interleukin-2
Survival
Recurrence
Radiotherapy

ASJC Scopus subject areas

  • Surgery

Cite this

Ratto, G. B., Melioli, C., Fantino, G., Tassara, E., Ponte, M., Angelini, M., ... Rovida, S. (1995). L'IMMUNOTERAPIA ADOTTIVA NEL TRATTAMENTO POST-CHIRURGICO DEL CARCINOMA POLMONARE NON A PICCOLE CELLULE. Chirurgia, 8(1-2), 82-87.

L'IMMUNOTERAPIA ADOTTIVA NEL TRATTAMENTO POST-CHIRURGICO DEL CARCINOMA POLMONARE NON A PICCOLE CELLULE. / Ratto, G. B.; Melioli, C.; Fantino, G.; Tassara, E.; Ponte, M.; Angelini, M.; Spessa, E.; Semino, C.; Rovida, S.

In: Chirurgia, Vol. 8, No. 1-2, 1995, p. 82-87.

Research output: Contribution to journalArticle

Ratto, GB, Melioli, C, Fantino, G, Tassara, E, Ponte, M, Angelini, M, Spessa, E, Semino, C & Rovida, S 1995, 'L'IMMUNOTERAPIA ADOTTIVA NEL TRATTAMENTO POST-CHIRURGICO DEL CARCINOMA POLMONARE NON A PICCOLE CELLULE', Chirurgia, vol. 8, no. 1-2, pp. 82-87.
Ratto GB, Melioli C, Fantino G, Tassara E, Ponte M, Angelini M et al. L'IMMUNOTERAPIA ADOTTIVA NEL TRATTAMENTO POST-CHIRURGICO DEL CARCINOMA POLMONARE NON A PICCOLE CELLULE. Chirurgia. 1995;8(1-2):82-87.
Ratto, G. B. ; Melioli, C. ; Fantino, G. ; Tassara, E. ; Ponte, M. ; Angelini, M. ; Spessa, E. ; Semino, C. ; Rovida, S. / L'IMMUNOTERAPIA ADOTTIVA NEL TRATTAMENTO POST-CHIRURGICO DEL CARCINOMA POLMONARE NON A PICCOLE CELLULE. In: Chirurgia. 1995 ; Vol. 8, No. 1-2. pp. 82-87.
@article{32947a3b62c242f6a7e4e5957de080e5,
title = "L'IMMUNOTERAPIA ADOTTIVA NEL TRATTAMENTO POST-CHIRURGICO DEL CARCINOMA POLMONARE NON A PICCOLE CELLULE",
abstract = "This study has been carried out to evaluate the efficacy of Adoptive Immunotherapy (AI) with TIL (Tumor Infiltrating Lymphocytes) cells and recombinant Interleukin-2 (rIL-2) in patients who underwent surgery for non small cell lung cancer (NSCLC) at Stage II, IIIa or IIIb. Seventy-one patients were stratified according to the disease Stage, randomized and treated with AI or standard therapies (Chemo-radiotherapy in Stage III; no therapy in Stage II). TIL cells, obtained from the removed specimens, were in vitro expanded and infused i.v. Subcutaneous administration of rIL-2, starting at the TIL infusion day, lasted for 3 months. For Stage II patients, the survival curve in the AI Group was similar to that in the Control Group. For Stage IIIa patients, survival tended to be higher in the AI Group with respect to the Control Group. For Stage IIIb patients, survival was significantly (p <0.05) better in the AI Group. The Performance Status, as far as Stage III patients are concerned, was improved in the AI Group, with respect to the Control Group. The number of intrathoracic recurrences was lower (50{\%}) in patients undergoing AI, while no difference between Groups was found for distant relapse.",
keywords = "Immunotherapy, Interleukin-2, Lung neoplasms, Lymphocytes",
author = "Ratto, {G. B.} and C. Melioli and G. Fantino and E. Tassara and M. Ponte and M. Angelini and E. Spessa and C. Semino and S. Rovida",
year = "1995",
language = "Italian",
volume = "8",
pages = "82--87",
journal = "Chirurgia (Turin)",
issn = "0394-9508",
publisher = "Minerva Medica",
number = "1-2",

}

TY - JOUR

T1 - L'IMMUNOTERAPIA ADOTTIVA NEL TRATTAMENTO POST-CHIRURGICO DEL CARCINOMA POLMONARE NON A PICCOLE CELLULE

AU - Ratto, G. B.

AU - Melioli, C.

AU - Fantino, G.

AU - Tassara, E.

AU - Ponte, M.

AU - Angelini, M.

AU - Spessa, E.

AU - Semino, C.

AU - Rovida, S.

PY - 1995

Y1 - 1995

N2 - This study has been carried out to evaluate the efficacy of Adoptive Immunotherapy (AI) with TIL (Tumor Infiltrating Lymphocytes) cells and recombinant Interleukin-2 (rIL-2) in patients who underwent surgery for non small cell lung cancer (NSCLC) at Stage II, IIIa or IIIb. Seventy-one patients were stratified according to the disease Stage, randomized and treated with AI or standard therapies (Chemo-radiotherapy in Stage III; no therapy in Stage II). TIL cells, obtained from the removed specimens, were in vitro expanded and infused i.v. Subcutaneous administration of rIL-2, starting at the TIL infusion day, lasted for 3 months. For Stage II patients, the survival curve in the AI Group was similar to that in the Control Group. For Stage IIIa patients, survival tended to be higher in the AI Group with respect to the Control Group. For Stage IIIb patients, survival was significantly (p <0.05) better in the AI Group. The Performance Status, as far as Stage III patients are concerned, was improved in the AI Group, with respect to the Control Group. The number of intrathoracic recurrences was lower (50%) in patients undergoing AI, while no difference between Groups was found for distant relapse.

AB - This study has been carried out to evaluate the efficacy of Adoptive Immunotherapy (AI) with TIL (Tumor Infiltrating Lymphocytes) cells and recombinant Interleukin-2 (rIL-2) in patients who underwent surgery for non small cell lung cancer (NSCLC) at Stage II, IIIa or IIIb. Seventy-one patients were stratified according to the disease Stage, randomized and treated with AI or standard therapies (Chemo-radiotherapy in Stage III; no therapy in Stage II). TIL cells, obtained from the removed specimens, were in vitro expanded and infused i.v. Subcutaneous administration of rIL-2, starting at the TIL infusion day, lasted for 3 months. For Stage II patients, the survival curve in the AI Group was similar to that in the Control Group. For Stage IIIa patients, survival tended to be higher in the AI Group with respect to the Control Group. For Stage IIIb patients, survival was significantly (p <0.05) better in the AI Group. The Performance Status, as far as Stage III patients are concerned, was improved in the AI Group, with respect to the Control Group. The number of intrathoracic recurrences was lower (50%) in patients undergoing AI, while no difference between Groups was found for distant relapse.

KW - Immunotherapy

KW - Interleukin-2

KW - Lung neoplasms

KW - Lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=0029008634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029008634&partnerID=8YFLogxK

M3 - Articolo

VL - 8

SP - 82

EP - 87

JO - Chirurgia (Turin)

JF - Chirurgia (Turin)

SN - 0394-9508

IS - 1-2

ER -